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ABSTRACT
Objectives: The purpose of this study was to analyze and evaluate evidence supporting curcumin lowering the systemic
inflammatory marker, CRP in humans. Methods: A systematic literature search was completed using PubMed and MEDLINE
databases. Results: After inclusion and exclusion criteria, 9 studies were evaluated, and the percent change of CRP blood levels
was calculated and analyzed. Results: The results for these studies show strong statistical significance for the C3 complex with
Bioperine and nano curcumin. Bioactive curcumin exhibits a higher percent decrease of blood level CRP than trials using only
curcumin or turmeric. Conclusion: Overall bioactive curcumin/ curcumin with Bioperine are alternative treatments for lowering
the systemic inflammation marker, CRP.
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INTRODUCTION
Curcumin (Curcuma longa) is the major bioactive component of the rhizomatous herbaceous perennial plant turmeric, a widely
used spice in Indian and Chinese medicine and widely consumed in the Asian diet.1,2 Curcumin (1,7-bis-4-hydroxy-3methoxyphenyl0-1,6-heptadiene-3,5-dione) also known as diferuloylmethane, is the primary polyphenol found in turmeric.2
Curcuma longa has been traditionally used in Asian countries as a medicinal and therapeutic herb for its antioxidant and antiinflammatory properties.3 Curcumin has been shown to modulate multiple signaling molecules and demonstrates activity at the
cellular level which supports its multiple health benefits for inflammatory conditions. 4,5 Even with its reported benefits, a major
problem with ingesting curcumin has been its poor bioavailability.6 Several additives have been tested to improve curcumins
bioavailability, one of which is piperine, the major active component of black pepper. Piperine has been associated with 2000%
increase in bioavailability for curcumin.6,7 When formulated with biodegradable nano particles by emulsion technique, the
curcumin is then entrapped in the particles and has demonstrated a 9 fold increase in oral bioavailability when compared to
piperine.8
CRP/Systemic Inflammation
C - reactive protein (CRP) is a polypeptide molecule of the pentrxains family and is normally synthesized primarily by the liver in
response to specific pro-inflammatory cytokines, especially interleukin-6 (IL-6). CRP is the primary marker of inflammation and a
protein of acute systemic inflammation and has been long been recognized as a useful marker for inflammatory conditions like
cardiovascular disease, Rheumatoid arthritis, and infection.9-12 Serum CRP levels can change rapidly from 10 -100 fold within 672 hours of an inflammatory event. CRP is not the only biomarker for inflammation status but is the most commonly used and is
an inexpensive method for evaluation.13-15 The elevated levels correlate to the onset and the extent of the inflammation
response. 16 The blood of healthy individuals has scarce amounts of CRP and rise robustly during tissue damage or inflammation
associated with trauma, infection/non-infectious diseases. It has been wrongly concluded that the biological actions of CRP are
only manifested when blood levels are elevated. It has been shown that CRP is an important mediator of biological activities
such as in the absence of blood elevation.17 The aim of this systematic review is to examine studies of the effect of curcumin,
nano-particle curcumin, and curcumin with bioperine on lowering the systemic inflammatory marker, CRP in humans.
METHODS
This systematic review was done following Preferred Reporting Items for Systematic Reviews ( PRISMA) guidelines and was
conducted by an independent researcher. Two databases were searched, PubMed and Medline on 9-30-21. The following
Medical Subject Headings (MeSH) were used: curcumin, bioactive curcumin, curcuminoids systemic inflammation, CRP, hsCRP, C - reactive protein. Full text articles were reviewed for inclusion and exclusion criteria. (See figure 1)
This review included any human research studies with participants aged 18 to 80 years. Only randomized control studies were
included. Non-primary research was excluded and clinical trials and randomized control trials (RCT) on curcumin and effects on
CRP and systemic inflammation were used. For the interest of bioavailability trials on nano-curcumin, curcumin and bioperine/
curcumin were included. In each clinical trial or RCT percent change of blood level CRP was calculated and P-values for each
outcome group were reported (see table 1). The Bias assessment tool used was the Cochrane risk-of-bias tool for randomized
trials.
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Records identified from*:
Medline (n=38
PubMed (n=36)
Other (n=1)

Records removed before
screening:
Duplicate records removed
(n = 15)
Records not meeting
inclusion or exclusion criteria
(n =15)
Records removed for other
reasons (n =9 )

Records screened abstracts
(n = 11)

Records excluded**Animal
(n = 1)

Reports sought for retrieval
(n =10 )

Full Article not available
(n =1 )

Full articles assessed for
eligibility
(n =9 )

Included

Reports excluded: 0

Studies included in review
(n =9 )

*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number
across all databases/registers).
**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

Figure 1. 2020 Flow Diagram for New Systematic Reviews Which Included Searches of Databases and Registers Only
RESULTS
Study selection & Study Characteristics
A total of 75 articles were found, 36 from PubMed, 38 from Medline and 1 from other sources. After duplicate removal and
excluding non-primary research, 15 remained, after excluding animal trials, 14 remained. The trials that measured CRP, C reactive protein and hs-CRP were included, leaving 9 trials. (See table 1).
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Table 1. Characteristics of Selected Trials Included in this Review
Author/
year

Type of
curcumin

Length of
intervention

number of
participants

Age range of
participants

Dosage of curcumin

Type of trial

Alvarenga,
2020

Orange, carrot,
curcumin juice

12 weeks

28

18 and older

Pilot randomized
double blind
controlled study

Rodrigues,
2021

curcuminoid

12 weeks

43

20-75

Afshar,
2020

Nano curcumin

12 weeks

60

18-80

2.5 g turmeric (95%
curcuminoids)
Control group received
juice without curcumin
1 g capsules
(standardized dry extract
96.84% curcuminoids)
Placebo group received
corn starch capsules
120 mg nano-curcumin
Placebo group received
paraffin soft gel capsules

Kocher,
2016

Curcumin
Demethoxycurcu
min
Bisdemethoxycurcum
in

6 weeks

32

17 men( 50 +- 20)
25 women( 52 +20)

Rahimnia,
2015

Curcuminoids/pipe
rine

6 weeks

40

5732 +- 8.78
57.57 +- 9.05

241.2 mg curcumin,47.1
mg DMC, 5.9 mg
BDMC(294.2 mg
curcuminoids)
placebo received 80.4
mg curcumin, 15.6 mg
DMC, 2.0 mg BDMC
1500 mg curcumin/15 mg
piperine

Panahi,
2015

C3 complexCurcumin/Bioperin
e

4 weeks

89

Groups were
matched in age

500 mg curcumin/5 mg
Bioperine

Panahi,
2012

C3 complexcurcumin/
Bioperine

4 weeks

96

37-59

1g

Samadian,
2017

Turmeric/
curcumin

12 weeks

71

18 and older

500 mg Tumeric/ 22.1
mg curcumin

Helli, 2020

Curcumin/ nano
curcumin

8 weeks

90

40-80

Group 1: 500 mg
curcumin
Group 2: 80mg nano
curcumin
Group 3: placebo

Randomized
double blind
placebocontrolled trial
Parallel
randomized
controlled clinical
trial
Randomized
double blind
crossover trial

Randomized
double blind
placebo
controlled trial
Randomized
double blind
placebo
controlled pilot
study
Randomized
double blind
placebo
controlled clinical
trial
Double blind
placebo
controlled
randomized
clinical trial
Random control
trial

A total of 549 subjects were enrolled among the 9 included trials. The subjects were human adults and included males and
females with an age range of 18-80. The participants in each trial were being evaluated for inflammation being caused by,
chronic kidney disease18-21 cardiovascular disease22,23 sulfur mustard intoxication,24,25 or osteoarthritis.26 The curcumin, nanocurcumin, and curcumin/bioperine dosages ranged from 80.4 mg-2.5g. Of the studies included, all were randomized trials and
incorporated blinding and placebo groups. Two out of the 9 trials had participants with high CRP levels which equates to 10 mg/L
and above (see table 2).17,20,24
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Table 2. CRP P-values/ percent change
Author/Year
Percent change CRP
Values curcumin group
Alvarenga, 2020
Rodrigues, 2021
Afshar, 2020
Kocher,2016
Rahimnia, 2015
Panahi, 2015
Panahi, 2012
Samadian, 2017
Helli, 2020

-47.36
+7.69
-46.71
0
-4.13
-34.09
-43.41
-37.09
Curcumin
-42.56

nano
-46.8

2

Percent change CRP
Values placebo
group
+13.79
-5.17
-3.47
-5.5
+4.4
-7.25
-9.48
+42.85
-0.79

Quality of Assessment and Risk of Bias
The risk of bias for the studies reviewed was assessed and it was found that there is a low bias across trials. Potential issues
with bias for some of the trials would be a lack of data22 and lower number of participants18,19,22,26 when compared to the other
trials included. Random allocation for participants was used in all trials included and participants and examiners were blinded
during the trials.
DISCUSSION
In summary, the results of these studies showed some evidence that supplementation with curcumin C3 complex with bioperine
and nano curcumin lowers CRP. While the findings from these studies exhibit progressive first steps in understanding clinical
applications of curcumin, limitations of studies limit conclusions. Study samples were small in 4 of the trials18,19,22,26 and the
duration of 4 of the trials22,24-26 were 6 weeks or less. Differences in formulation and dosage also contribute to limitations and
effect consistency across trials. Nano curcumin and Curcumin C3 complex with bioperine exhibit better bioavailability and nano
curcumin appears to be more effective in lower doses (80-120mg) when compared to curcumin alone.20,21,23,25
C-reactive protein levels are an indication of the inflammatory state in the human body and can be related to acute inflammation,
infection and autoimmunity.11 CRP values will vary widely from person to person. 3-10 mg/L levels are considered to be in the
category of low grade inflammation resulting in metabolic stress and are conducive with atherosclerosis, insulin resistance,
hypertension, etc. Clinically significant levels or CRP equate to ≥ 10 mg/L and levels above 100 mg/L indicate severe infection.17
In addition to serving as a marker for acute infection, elevated CRP levels have been associated with chronic conditions such as
cardiovascular disease. It is believed that while acute inflammation can be advantageous in promoting healing and recovery,
chronic inflammation can be detrimental and is thus connected with many chronic conditions. Chronically elevated CRP is
indicative of chronic inflammation and its early detection may help in the prevention and treatment of such conditions. It is
believed that CRP is stimulated by Interleukin-6 during times of trauma, or disease, therefore CRP can be reflective of overall
systemic inflammation without having to report multiple biomarkers.11,12,16
Limitations
Limitations in the studies included in this review may be due to lack of proper control for confounding variables such as exercise,
use of other supplements, use of over-the-counter medications, or other behaviors that may impact inflammation. Another
limitation of homogeneity in participant populations. Out of the 9 trials, curcumin was tested in four Hemodialysis trials18-21 two
sulfur mustard intoxication trials24,25 two cardiovascular trials22,23 and one osteoarthritis trial.26 Implications for the use of curcumin
in healthy and subclinical populations are therefore challenging to determine.
Recommendations for Future Research
Future studies should utilize bioavailable curcumin formulas and should study healthy, subclinical populations and populations
with chronic disease states in order to determine potential benefits of curcumin supplementation.20,23-26 Dosage needs to be
established for adequate treatment however tolerability of doses (84.4 mg- 2.5g) across trials was acceptable with minimal
participant drop out and side effects. This will lead to better information for dosage and treatment for different disease states that
are affected by inflammation.
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CONCLUSION
Out of the 9 trials included in this systematic review, 5 of them utilized bioactive components, bioperine, nano, with the
curcumin.20,23-26 The results of this systematic review suggest that bioactive curcumin may be effective in lowering CRP in
individuals suffering from inflammatory conditions Overall Bioactive Curcumin/ Curcumin with Bioperine may be viable alternative
treatments for lowering the primary marker of systemic inflammation, CRP.
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